+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Psychedelic API Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
Psychedelic API Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
New

Psychedelic API Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 190 Pages
  • July 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 5918226
Description Jump to:
The global psychedelic active pharmaceutical ingredient (API) market is experiencing unprecedented momentum, driven by increasing clinical validation of psychedelic compounds for mental health treatments. From their experimental origins, psychedelic APIs like psilocybin, MDMA, LSD, and DMT are becoming essential ingredients in next-generation therapies for treatment-resistant depression (TRD), PTSD, anxiety, and addiction. According to recent industry analysis, the market is poised to grow from a valuation of USD 2.6 billion in 2025 to USD 5.9 billion by 2032, registering a CAGR of 12.42% over the forecast period.

Market Insights

The shift toward psychedelic-assisted therapy has significantly amplified demand for pharmaceutical-grade psychedelic APIs. Institutions such as Johns Hopkins Center for Psychedelic and Consciousness Research and the Multidisciplinary Association for Psychedelic Studies (MAPS) have propelled research efforts and public interest. Advancements in API-grade psilocybin, MDMA formulations, and novel delivery systems are helping transform the once-taboo class of drugs into credible treatment options.

With expanding clinical trial data and breakthrough therapy designations granted by regulatory authorities, pharmaceutical companies are investing heavily in high-purity psychedelic substances. As global mental health disorders escalate, the use of psychedelic APIs is emerging as a powerful therapeutic tool supported by strong scientific evidence.

Market Drivers

The market is being driven by growing awareness of the limitations of traditional antidepressants and the rising incidence of treatment-resistant conditions. Breakthrough clinical results from trials involving compounds like psilocybin and MDMA have highlighted their efficacy in achieving symptom remission in hard-to-treat patients.

Key drivers include:

  • Increasing number of clinical trials showing success in psychedelic-assisted psychotherapy.
  • Regulatory reforms enabling clinical use of controlled substances for mental health disorders.
  • Rising investment by pharmaceutical firms in the R&D of synthetic psychedelic compounds.
  • Growing preference for GMP-grade APIs to ensure clinical safety and quality.

Business Opportunity

Strategic partnerships between API manufacturers and pharma companies are opening avenues for scalable, cost-effective production of high-quality psychedelic APIs. Companies like Compass Pathways, MindMed, and ATAI Life Sciences are collaborating with contract manufacturing organizations to enhance consistency, purity, and regulatory compliance.

Recent developments in bio-synthetic and synthetic psychedelic production techniques are helping overcome barriers related to natural compound extraction and scalability. Pharma-API collaborations are enabling faster commercialization and broader clinical applications, supporting wider adoption of psychedelic-based treatments.

Regional Analysis

North America dominates the global psychedelic API market, with the U.S. leading the way through favorable regulatory conditions, clinical research investment, and advanced pharmaceutical manufacturing infrastructure. Backed by institutions such as the American Psychological Association and the FDA’s Breakthrough Therapy designation, the U.S. continues to be a pioneer in this field.

Europe is fast emerging as a major player, thanks to landmark government-backed research initiatives exploring psychedelic treatments for depression and PTSD. Countries like the U.K., Germany, and the Netherlands are contributing to the market through innovative clinical trials and progressive regulatory support.

Asia Pacific is gaining traction due to growing demand for mental health therapies, increased investment in biopharmaceutical innovation, and the presence of cost-effective API manufacturing hubs in China and India. Japan and South Korea are also investing in advanced drug delivery systems and personalized treatment frameworks.

Key Players

Leading companies in the psychedelic API space are actively expanding their portfolios through innovation, partnerships, and regulatory approvals. Key market participants include:

  • Core One Labs Inc.
  • Cayman Chemical Company (Matreya)
  • COMPASS Pathways plc
  • Beckley Psytech
  • Atai Life Sciences
  • Tryp Therapeutics
  • Filament Health
  • Ceruvia Lifesciences, LLC
  • BetterLife Pharma
  • Psygen Pharmaceutical
  • Mindset Pharma
These companies are spearheading efforts to standardize psychedelic drug development, expand GMP-certified production capabilities, and support the medical mainstreaming of psychedelic compounds.

Market Segmentation

By Product Type

  • API-Grade Psilocybin
  • API-Grade DMT
  • LSD API
  • MDMA API
  • Ketamine API
  • Others

By API Compound

  • Active Plant Components
  • Novel Synthetic Compounds
  • Metabolites
  • Isotopically Labelled Standards

By Source

  • Natural
  • Synthetic
  • Bio-Synthetic

By Grade

  • GMP
  • Non-GMP

By Application

  • Clinical
  • Research

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Psychedelic API Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Psychedelic API Market Outlook, 2019-2032
3.1. Global Psychedelic API Market Outlook, by Product, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. API-Grade Psilocybin
3.1.1.2. API-Grade DMT
3.1.1.3. LSD API
3.1.1.4. MDMA API
3.1.1.5. Ketamine API
3.1.1.6. Others
3.2. Global Psychedelic API Market Outlook, by API Compound, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Active Plant Components
3.2.1.2. Novel Synthetic Compounds
3.2.1.3. Metabolites
3.2.1.4. Isotopically Labelled Standards
3.3. Global Psychedelic API Market Outlook, by Source, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Natural
3.3.1.2. Synthetic
3.3.1.3. Bio-Synthetic
3.4. Global Psychedelic API Market Outlook, by Grade, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. GMP
3.4.1.2. Non-GMP
3.4.1.3. Others
3.5. Global Psychedelic API Market Outlook, by Application, Value (US$ Bn), 2019-2032
3.5.1. Key Highlights
3.5.1.1. Clinical
3.5.1.2. Research
3.6. Global Psychedelic API Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.6.1. Key Highlights
3.6.1.1. North America
3.6.1.2. Europe
3.6.1.3. Asia Pacific
3.6.1.4. Latin America
3.6.1.5. Middle East & Africa
4. North America Psychedelic API Market Outlook, 2019-2032
4.1. North America Psychedelic API Market Outlook, by Product, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. API-Grade Psilocybin
4.1.1.2. API-Grade DMT
4.1.1.3. LSD API
4.1.1.4. MDMA API
4.1.1.5. Ketamine API
4.1.1.6. Others
4.2. North America Psychedelic API Market Outlook, by API Compound, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Active Plant Components
4.2.1.2. Novel Synthetic Compounds
4.2.1.3. Metabolites
4.2.1.4. Isotopically Labelled Standards
4.3. North America Psychedelic API Market Outlook, by Source, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Natural
4.3.1.2. Synthetic
4.3.1.3. Bio-Synthetic
4.4. North America Psychedelic API Market Outlook, by Grade, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. GMP
4.4.1.2. Non-GMP
4.4.1.3. Others
4.5. North America Psychedelic API Market Outlook, by Application, Value (US$ Bn), 2019-2032
4.5.1. Key Highlights
4.5.1.1. Clinical
4.5.1.2. Research
4.5.2. BPS Analysis/Market Attractiveness Analysis
4.6. North America Psychedelic API Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.6.1. Key Highlights
4.6.1.1. U.S. Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
4.6.1.2. U.S. Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
4.6.1.3. U.S. Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
4.6.1.4. U.S. Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
4.6.1.5. U.S. Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
4.6.1.6. Canada Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
4.6.1.7. Canada Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
4.6.1.8. Canada Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
4.6.1.9. Canada Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
4.6.1.10. Canada Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
4.6.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Psychedelic API Market Outlook, 2019-2032
5.1. Europe Psychedelic API Market Outlook, by Product, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. API-Grade Psilocybin
5.1.1.2. API-Grade DMT
5.1.1.3. LSD API
5.1.1.4. MDMA API
5.1.1.5. Ketamine API
5.1.1.6. Others
5.2. Europe Psychedelic API Market Outlook, by API Compound, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Active Plant Components
5.2.1.2. Novel Synthetic Compounds
5.2.1.3. Metabolites
5.2.1.4. Isotopically Labelled Standards
5.3. Europe Psychedelic API Market Outlook, by Source, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Natural
5.3.1.2. Synthetic
5.3.1.3. Bio-Synthetic
5.4. Europe Psychedelic API Market Outlook, by Grade, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. GMP
5.4.1.2. Non-GMP
5.4.1.3. Others
5.5. Europe Psychedelic API Market Outlook, by Application, Value (US$ Bn), 2019-2032
5.5.1. Key Highlights
5.5.1.1. Clinical
5.5.1.2. Research
5.5.2. BPS Analysis/Market Attractiveness Analysis
5.6. Europe Psychedelic API Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.6.1. Key Highlights
5.6.1.1. Germany Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
5.6.1.2. Germany Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
5.6.1.3. Germany Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
5.6.1.4. Germany Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
5.6.1.5. Germany Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
5.6.1.6. U.K. Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
5.6.1.7. U.K. Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
5.6.1.8. U.K. Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
5.6.1.9. U.K. Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
5.6.1.10. U.K. Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
5.6.1.11. France Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
5.6.1.12. France Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
5.6.1.13. France Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
5.6.1.14. France Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
5.6.1.15. France Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
5.6.1.16. Italy Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
5.6.1.17. Italy Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
5.6.1.18. Italy Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
5.6.1.19. Italy Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
5.6.1.20. Italy Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
5.6.1.21. Turkey Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
5.6.1.22. Turkey Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
5.6.1.23. Turkey Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
5.6.1.24. Turkey Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
5.6.1.25. Turkey Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
5.6.1.26. Russia Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
5.6.1.27. Russia Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
5.6.1.28. Russia Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
5.6.1.29. Russia Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
5.6.1.30. Russia Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
5.6.1.31. Rest of Europe Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
5.6.1.32. Rest of Europe Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
5.6.1.33. Rest of Europe Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
5.6.1.34. Rest of Europe Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
5.6.1.35. Rest of Europe Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
5.6.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Psychedelic API Market Outlook, 2019-2032
6.1. Asia Pacific Psychedelic API Market Outlook, by Product, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. API-Grade Psilocybin
6.1.1.2. API-Grade DMT
6.1.1.3. LSD API
6.1.1.4. MDMA API
6.1.1.5. Ketamine API
6.1.1.6. Others
6.2. Asia Pacific Psychedelic API Market Outlook, by API Compound, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Active Plant Components
6.2.1.2. Novel Synthetic Compounds
6.2.1.3. Metabolites
6.2.1.4. Isotopically Labelled Standards
6.3. Asia Pacific Psychedelic API Market Outlook, by Source, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Natural
6.3.1.2. Synthetic
6.3.1.3. Bio-Synthetic
6.4. Asia Pacific Psychedelic API Market Outlook, by Grade, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. GMP
6.4.1.2. Non-GMP
6.4.1.3. Others
6.5. Asia Pacific Psychedelic API Market Outlook, by Application, Value (US$ Bn), 2019-2032
6.5.1. Key Highlights
6.5.1.1. Clinical
6.5.1.2. Research
6.5.2. BPS Analysis/Market Attractiveness Analysis
6.6. Asia Pacific Psychedelic API Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.6.1. Key Highlights
6.6.1.1. China Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
6.6.1.2. China Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
6.6.1.3. China Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
6.6.1.4. China Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
6.6.1.5. China Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
6.6.1.6. Japan Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
6.6.1.7. Japan Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
6.6.1.8. Japan Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
6.6.1.9. Japan Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
6.6.1.10. Japan Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
6.6.1.11. South Korea Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
6.6.1.12. South Korea Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
6.6.1.13. South Korea Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
6.6.1.14. South Korea Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
6.6.1.15. South Korea Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
6.6.1.16. India Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
6.6.1.17. India Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
6.6.1.18. India Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
6.6.1.19. India Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
6.6.1.20. India Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
6.6.1.21. Southeast Asia Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
6.6.1.22. Southeast Asia Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
6.6.1.23. Southeast Asia Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
6.6.1.24. Southeast Asia Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
6.6.1.25. Southeast Asia Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
6.6.1.26. Rest of Asia Pacific Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
6.6.1.27. Rest of Asia Pacific Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
6.6.1.28. Rest of Asia Pacific Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
6.6.1.29. Rest of Asia Pacific Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
6.6.1.30. Rest of Asia Pacific Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
6.6.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Psychedelic API Market Outlook, 2019-2032
7.1. Latin America Psychedelic API Market Outlook, by Product, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. API-Grade Psilocybin
7.1.1.2. API-Grade DMT
7.1.1.3. LSD API
7.1.1.4. MDMA API
7.1.1.5. Ketamine API
7.1.1.6. Others
7.2. Latin America Psychedelic API Market Outlook, by API Compound, Value (US$ Bn), 2019-2032
7.2.1. Key Highlights
7.2.1.1. Active Plant Components
7.2.1.2. Novel Synthetic Compounds
7.2.1.3. Metabolites
7.2.1.4. Isotopically Labelled Standards
7.3. Latin America Psychedelic API Market Outlook, by Source, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Natural
7.3.1.2. Synthetic
7.3.1.3. Bio-Synthetic
7.4. Latin America Psychedelic API Market Outlook, by Grade, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. GMP
7.4.1.2. Non-GMP
7.4.1.3. Others
7.5. Latin America Psychedelic API Market Outlook, by Application, Value (US$ Bn), 2019-2032
7.5.1. Key Highlights
7.5.1.1. Clinical
7.5.1.2. Research
7.5.2. BPS Analysis/Market Attractiveness Analysis
7.6. Latin America Psychedelic API Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.6.1. Key Highlights
7.6.1.1. Brazil Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
7.6.1.2. Brazil Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
7.6.1.3. Brazil Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
7.6.1.4. Brazil Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
7.6.1.5. Brazil Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
7.6.1.6. Mexico Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
7.6.1.7. Mexico Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
7.6.1.8. Mexico Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
7.6.1.9. Mexico Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
7.6.1.10. Mexico Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
7.6.1.11. Argentina Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
7.6.1.12. Argentina Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
7.6.1.13. Argentina Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
7.6.1.14. Argentina Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
7.6.1.15. Argentina Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
7.6.1.16. Rest of Latin America Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
7.6.1.17. Rest of Latin America Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
7.6.1.18. Rest of Latin America Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
7.6.1.19. Rest of Latin America Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
7.6.1.20. Rest of Latin America Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
7.6.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Psychedelic API Market Outlook, 2019-2032
8.1. Middle East & Africa Psychedelic API Market Outlook, by Product, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. API-Grade Psilocybin
8.1.1.2. API-Grade DMT
8.1.1.3. LSD API
8.1.1.4. MDMA API
8.1.1.5. Ketamine API
8.1.1.6. Others
8.2. Middle East & Africa Psychedelic API Market Outlook, by API Compound, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Active Plant Components
8.2.1.2. Novel Synthetic Compounds
8.2.1.3. Metabolites
8.2.1.4. Isotopically Labelled Standards
8.3. Middle East & Africa Psychedelic API Market Outlook, by Source, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Natural
8.3.1.2. Synthetic
8.3.1.3. Bio-Synthetic
8.4. Middle East & Africa Psychedelic API Market Outlook, by Grade, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. GMP
8.4.1.2. Non-GMP
8.4.1.3. Others
8.5. Middle East & Africa Psychedelic API Market Outlook, by Application, Value (US$ Bn), 2019-2032
8.5.1. Key Highlights
8.5.1.1. Clinical
8.5.1.2. Research
8.5.2. BPS Analysis/Market Attractiveness Analysis
8.6. Middle East & Africa Psychedelic API Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.6.1. Key Highlights
8.6.1.1. GCC Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
8.6.1.2. GCC Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
8.6.1.3. GCC Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
8.6.1.4. GCC Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
8.6.1.5. GCC Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
8.6.1.6. South Africa Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
8.6.1.7. South Africa Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
8.6.1.8. South Africa Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
8.6.1.9. South Africa Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
8.6.1.10. South Africa Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
8.6.1.11. Egypt Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
8.6.1.12. Egypt Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
8.6.1.13. Egypt Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
8.6.1.14. Egypt Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
8.6.1.15. Egypt Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
8.6.1.16. Nigeria Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
8.6.1.17. Nigeria Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
8.6.1.18. Nigeria Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
8.6.1.19. Nigeria Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
8.6.1.20. Nigeria Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
8.6.1.21. Rest of Middle East & Africa Psychedelic API Market by Product, Value (US$ Bn), 2019-2032
8.6.1.22. Rest of Middle East & Africa Psychedelic API Market by API Compound, Value (US$ Bn), 2019-2032
8.6.1.23. Rest of Middle East & Africa Psychedelic API Market by Source, Value (US$ Bn), 2019-2032
8.6.1.24. Rest of Middle East & Africa Psychedelic API Market by Grade, Value (US$ Bn), 2019-2032
8.6.1.25. Rest of Middle East & Africa Psychedelic API Market by Application, Value (US$ Bn), 2019-2032
8.6.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Source vs by API Compound Heat map
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Core One Labs Inc.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Cayman Chemical Company (Matreya)
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. COMPASS Pathways plc
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Beckley Psytech
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Atai Life Sciences
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Tryp Therapeutics
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Filament Health
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Ceruvia Lifesciences, LLC
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. BetterLife Pharma
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Psygen Pharmaceutical
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. Mindset Pharma
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Core One Labs Inc.
  • Cayman Chemical Company (Matreya)
  • COMPASS Pathways plc
  • Beckley Psytech
  • Atai Life Sciences
  • Tryp Therapeutics
  • Filament Health
  • Ceruvia Lifesciences, LLC
  • BetterLife Pharma
  • Psygen Pharmaceutical
  • Mindset Pharma

Related Topics

Related Reports

Tryptamines API Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Tryptamines API Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 275 Pages
  • Global
From
Active Pharmaceutical Ingredient Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Active Pharmaceutical Ingredient Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 267 Pages
  • Global
From
Vinca Alkaloid Active Pharmaceutical Ingredient (API) Global Market Report 2025 - Product Image

Vinca Alkaloid Active Pharmaceutical Ingredient (API) Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Active Pharmaceutical Ingredient (API) Intermediate Global Market Report 2025 - Product Image

Active Pharmaceutical Ingredient (API) Intermediate Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Active Pharmaceutical Ingredients Market Size, Share, Trends and Forecast by Drug Type, Type of Manufacturer, Type of Synthesis, Therapeutic Application, and Region, 2025-2033 - Product Image

Active Pharmaceutical Ingredients Market Size, Share, Trends and Forecast by Drug Type, Type of Manufacturer, Type of Synthesis, Therapeutic Application, and Region, 2025-2033

  • Report
  • 140 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.